Latest news with #lifeSciences
Yahoo
a day ago
- Business
- Yahoo
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025
SAN DIEGO, July 28, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its second quarter 2025 financial and operating results after the market close on Monday, August 11, 2025, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m. ET. To participate in the conference call by telephone, dial (800) 267-6316 or (203) 518-9783 and reference Maravai LifeSciences, Conference ID MARAVAI. The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. CONTACT: Contact Information: Deb Hart Maravai LifeSciences + 1 858-988-5917 ir@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
a day ago
- Business
- Globe and Mail
Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock
Carlsbad, CA, July 28, 2025 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN) ("Qualigen" or the "Company"), a life sciences company focused on developing platform treatments for adult and pediatric cancers with the potential for orphan drug designations, today announced that it has entered into definitive securities purchase agreements with several institutional and accredited investors for the sale of its Series A-3 Preferred Stock. The private placement closed on July 28, 2025. The Company issued and sold an aggregate of 4,500 shares of Series A-3 Preferred Stock, with a stated value of $1,000 per share, for aggregate gross proceeds of $4.5 million, before deducting placement agent fees and other offering expenses. The Series A-3 Preferred Stock is initially convertible into an aggregate of 1,607,143 shares of common stock of the Company at a conversion price of $2.80 per share, subject to adjustment in accordance with the terms of the Series A-3 Preferred Stock Certificate of Designation. Univest, LLC acted as the exclusive placement agent for the offering. The Company intends to use the net proceeds from the sale of the Series A-3 Preferred Stock for working capital purposes. The shares of Series A-3 Preferred Stock were offered and issued in a private placement under Section 4(a)(2) and/or Rule 506(b) of Regulation D under the Securities Act of 1933 and have not been registered under the Securities Act or applicable state securities laws. Accordingly, the shares of Series A-3 Preferred Stock and the underlying shares of common stock may not be offered or sold in the United States unless registration with the Securities and Exchange Commission (the "SEC") or an applicable exemption from such registration requirements. The Company has agreed to file a registration statement with the SEC covering the resale of the shares of common stock underlying the Series A-3 Preferred Stock within 45 days after the closing date. This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. About Qualigen Therapeutics, Inc. Qualigen Therapeutics, Inc. (NASDAQ: QLGN) is a clinical-stage biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases. The Company's pipeline includes QN-302, a selective G-quadruplex inhibitor targeting various tumor types including pancreatic cancer; QN-247, a nucleolin-targeting compound for hematologic malignancies; and a family of small-molecule RAS oncogene protein-protein interaction inhibitors. Each of these programs is designed to address areas of high unmet medical need, with the potential for orphan drug designation. Qualigen is committed to advancing its therapeutic pipeline to improve patient outcomes and create long-term value for shareholders. For more information about Qualigen Therapeutics, Inc., please visit Forward-Looking Statements This press release contains 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are based on current expectations, estimates, assumptions, and projections about future events and involve inherent risks and uncertainties. These forward-looking statements include, but are not limited to, statements the filing of a resale registration statement, and the Company's future business plans and strategies. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' 'may,' 'will,' 'could,' 'would,' 'should,' 'continues,' and similar expressions are intended to identify such forward-looking statements. Actual results could differ materially from those projected due to a number of factors, including risks related to the Company's ability to successfully develop and commercialize its product candidates, regulatory developments, market conditions, the Company's ability to maintain compliance with Nasdaq listing requirements, and other risks described in the Company's filings with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Yahoo
6 days ago
- Business
- Yahoo
Azenta Announces Fiscal 2025 Third Quarter Earnings Conference Call and Webcast
BURLINGTON, Mass., July 23, 2025 /PRNewswire/ -- Azenta, Inc. (Nasdaq: AZTA) will announce fiscal third quarter 2025 earnings which ended on June 30, 2025, on Tuesday August 5, 2025, before the market opens. The Company will host a conference call and live webcast to discuss its financial results on the same day, Tuesday, August 5, 2025, at 8:30 a.m. Eastern Time. Analysts, investors and members of the media can access the live webcast via the Azenta website at A replay will be available beginning at 8:30 a.m. ET on August 6, 2025. About Azenta Life Sciences Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey. Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit INVESTOR CONTACTS:Yvonne PerronVice President, Financial Planning & Analysis, and Investor Relationsir@ Sherry View original content to download multimedia: SOURCE Azenta Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
Why Azenta (AZTA) Stock Is Up Today
What Happened? Shares of life sciences company Azenta (NASDAQ:AZTA) jumped 5.7% in the afternoon session after the investment firm Stephens initiated coverage on the life sciences company. The firm assigned an "equal weight" rating to the stock and set a price target of $35.00 per share. An "equal weight" rating suggests that the analyst believes the stock will perform in line with the average of the other stocks the analyst covers. This new coverage from a Wall Street firm can bring increased attention to a company, often leading to higher trading volume as investors digest the new rating and price target. The initiation comes after a period of volatility for the stock, which has seen significant price swings over the past year. After the initial pop the shares cooled down to $32.87, up 4.9% from previous close. Is now the time to buy Azenta? Access our full analysis report here, it's free. What Is The Market Telling Us Azenta's shares are very volatile and have had 26 moves greater than 5% over the last year. In that context, today's move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business. The previous big move we wrote about was 4 days ago when the stock dropped 3.7% as several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like Elevance Health and Humana seeing declines due to an analyst downgrade and a lost lawsuit regarding Medicare bonus payments, respectively. Additionally, some pharmaceutical and biotech companies experienced sharp drops following unfavorable news; for instance, Sarepta Therapeutics plunged after a report indicated another patient death tied to its experimental gene therapy, and GSK's blood cancer drug dosage was voted against by the FDA advisory committee. Broader market sentiment, including concerns about rising costs and inadequate pricing for 2025 plans among health insurers, also contributed to the downward pressure on healthcare equities. Azenta is down 34.3% since the beginning of the year, and at $32.87 per share, it is trading 47.2% below its 52-week high of $62.29 from July 2024. Investors who bought $1,000 worth of Azenta's shares 5 years ago would now be looking at an investment worth $706.19. Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-07-2025
- Business
- Yahoo
Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline
Danaher Corp (NYSE:DHR) on Tuesday reported second-quarter 2025 sales of $5.94 billion, up 3.5% year-over-year, beating the consensus of $5.84 billion. The life science giant reported adjusted earnings of $1.80 per share, beating the consensus of $1.64. Non-GAAP core revenue increased 1.5% year over year, compared to the expectations of a growth in low single digits year over year. Operating cash flow was $1.3 billion, and non-GAAP free cash flow was $1.1 billion. Danaher's second-quarter adjusted operating profit margin of 27.3% exceeded expectations of around 25.5%.Biotechnology sales increased to $1.85 billion compared to $1.71 billion a year ago, with core growth of 6%. Sales in the Life Sciences segment remained flat at $1.78 billion, and diagnostic sales increased from $2.26 billion to $2.31 billion. The company said, "DBS-driven execution, paired with another quarter of +HSD growth in Bioprocessing and disciplined cost management, enabled us to exceed our Q2 adjusted EPS and cash flow expectations." Guidance Danaher raised fiscal 2025 adjusted earnings guidance from $7.60-$7.75 per share to $7.70-$7.80, compared to the consensus of $7.70. The company cites good traction on cost initiatives. View more earnings on DHR Danaher reaffirms that in fiscal year 2025, non-GAAP core revenue will grow by approximately 3% year over year. Cepheid 2025 respiratory revenues will be around $1.7 billion. The company expects an adjusted operating profit margin of around 25.5%. Biotechnology core revenue growth is expected to be approximately 6% for the third quarter of 2025 and around 7% for the fiscal year 2025. Life sciences core revenue will remain flat for the third quarter and fiscal year 2025. Diagnostics sales are expected to increase in the low single digits in the third quarter and flat to low single digits in fiscal year 2025. Management update Danaher announced Matthew Gugino, currently group CFO of Life Sciences Innovations Group and VP of Financial Planning & Analysis, will succeed Matthew McGrew as Danaher's CFO, effective February 28, 2026. Analyst Opinion William Blair writes that the macro backdrop for life science tools and bioprocessing companies was anything but sanguine in the second quarter, with escalating concerns surrounding the funding environment, tariffs, MFN, and whether these uncertainties resulted in a slowdown in the overall demand environment." Danaher's results suggest that was not the case, at least in the second quarter, particularly within bioprocessing. Analyst Matt Larew maintains the Outperform rating. Price Action: DHR stock is trading 0.68% higher at $189.34 at the last check on Tuesday. Read Next:Photo via Shutterstock Latest Ratings for DHR Date Firm Action From To Jan 2022 Wells Fargo Maintains Overweight Jan 2022 Barclays Maintains Overweight Jan 2022 Bernstein Initiates Coverage On Outperform View More Analyst Ratings for DHR View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? DANAHER (DHR): Free Stock Analysis Report This article Danaher Lifts 2025 Earnings Outlook Amid Biotech Growth, Cost Discipline originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Errore nel recupero dei dati Effettua l'accesso per consultare il tuo portafoglio Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati Errore nel recupero dei dati
